Investor · 21 deals
Investment fund and incubator for biomedical research discoveries
Melbourne, VIC
Every published round Brandon BioCatalyst took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted, and a place in one of its own programs is under Cohorts.
Everyone Brandon BioCatalyst has named to a program in published coverage. A place in a program is not a raise: the cheque is the figure recorded with the place, which is the program's standard terms where we hold them, and a blank is one we don't.
Companies Brandon BioCatalyst has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| RAGE Biotech | 19 Jul 2022, Grant | 1 | 0 | |
| Alyra Biotech | 20 Jul 2022, Accelerator | 1 | 1 | |
| Axelia Oncology | 20 Jul 2022, Accelerator | 1 | 1 | |
| Carsinosa | 20 Jul 2022, Accelerator | 1 | 1 | |
| Cassowary Pharma | 20 Jul 2022, Accelerator | 1 | 1 | |
| Denteric | 20 Jul 2022, Accelerator | 1 | 1 | |
| FLEX Immunotherapeutics | 20 Jul 2022, Accelerator | 1 | 1 | |
| Genium | 20 Jul 2022, Accelerator | 1 | 1 | |
| George Medicines | 20 Jul 2022, Accelerator | 1 | 1 | |
| LASEREDD Therapeutics | 20 Jul 2022, Accelerator | 1 | 1 | |
| Liperate Therapeutics | 20 Jul 2022, Accelerator | 1 | 1 | |
| Mirugen | 20 Jul 2022, Accelerator | 1 | 1 | |
| MPI Biotech | 20 Jul 2022, Accelerator | 1 | 1 | |
| Nelcanen Therapeutics | 20 Jul 2022, Accelerator | 1 | 1 | |
| Omega-one Therapeutics | 20 Jul 2022, Accelerator | 1 | 1 | |
| Phrenix Therapeutics | 20 Jul 2022, Accelerator | 1 | 1 | |
| Azura Ophthalmics | 17 Aug 2022, Grant | 2 | 2 | |
| OccuRx | Online casino platform offering slots and table games | 5 Sep 2022, Accelerator | 2 | 2 |
| AAVec Bio | 2 Jun 2023, Accelerator | 1 | 1 | |
| AMT Bio | 2 Jun 2023, Accelerator | 1 | 1 | |
| BioBandage | 2 Jun 2023, Accelerator | 1 | 1 | |
| Cincera Therapeutics | 2 Jun 2023, Accelerator | 1 | 1 | |
| CoraMetix Pty Ltd | 2 Jun 2023, Accelerator | 1 | 1 | |
| Cyteph | 2 Jun 2023, Accelerator | 1 | 1 | |
| DesmoX | 2 Jun 2023, Accelerator | 1 | 1 | |
| Drug discovery platform targeting polynucleotides | 2 Jun 2023, Accelerator | 1 | 1 | |
| Exosome Biosciences | 2 Jun 2023, Accelerator | 1 | 1 | |
| Flavivirus vaccine platform | 2 Jun 2023, Accelerator | 1 | 1 | |
| Fovero Therapeutics | 2 Jun 2023, Accelerator | 1 | 1 | |
| Kimaritec | 2 Jun 2023, Accelerator | 1 | 1 | |
| Micromune Therapeutics | 2 Jun 2023, Accelerator | 1 | 1 | |
| Myrio Therapeutics | 2 Jun 2023, Accelerator | 1 | 1 | |
| Proxima Bio | 2 Jun 2023, Accelerator | 1 | 1 | |
| Sycura Therapeutics | 2 Jun 2023, Accelerator | 1 | 1 | |
| xCystence Bio | 2 Jun 2023, Accelerator | 1 | 1 | |
| Polyactiva | 2024, Grant | 2 | 2 | |
| Telethon Kids Institute | 29 Feb 2024, Accelerator | 1 | 1 | |
| University of Melbourne | 29 Feb 2024, Accelerator | 1 | 1 | |
| University of Western Australia | 29 Feb 2024, Accelerator | 1 | 1 | |
| Spritz-OM | 1 Mar 2024, Accelerator | 1 | 1 | |
| GPN Vaccines | May 2024, Grant | 2 | 2 | |
| Currus Biologics | 6 May 2024, Grant | 2 | 2 | |
| ENA Respiratory | Antiviral nasal spray to prevent severe respiratory viral infections | 6 May 2024, Grant | 2 | 2 |
| Frontier Inflammasome Therapeutics | 6 May 2024, Grant | 3 | 2 | |
| OncoStrike Biopharma | 6 May 2024, Grant | 2 | 2 | |
| Respirion | 6 May 2024, Grant | 2 | 2 | |
| Setonix Pharmaceuticals | 6 May 2024, Grant | 2 | 2 | |
| Cytophenix | 10 Sep 2024, Accelerator | 1 | 1 | |
| GILZRx | 10 Sep 2024, Accelerator | 1 | 1 | |
| Myostellar | 10 Sep 2024, Accelerator | 1 | 1 | |
| ProKardia | 5 May 2025, Accelerator | 1 | 0 | |
| Aleris Therapeutics | 12 Aug 2026, Grant | 2 | 1 | |
| Luma Bio | 12 Aug 2026, Grant | 2 | 1 | |
| Navier Medical Ltd | 12 Aug 2026, Grant | 2 | 1 | |
| Neurotologix | 12 Aug 2026, Grant | 2 | 1 | |
| WeGuide | 12 Aug 2026, Grant | 2 | 1 | |
| Kinoxis Therapeutics | 23 Sep 2026, Accelerator | 1 | 1 |
Companies Brandon BioCatalyst's own portfolio page lists that no published round yet places it in. The page is the source; the round is being looked for.
| Company | Site |
|---|---|
| Allay Therapeutics | - |
| Aravax | - |
| CatalYm | - |
| Certa Therapeutics | - |
| EBR Systems | - |
| Glyscend | - |
| MycRx | - |
| Myricx Pharma | - |
| NRG Therapeutics | - |
| OncoRes Medical | - |
| Pathios Therapeutics | - |
| Pheon Therapeutics | - |
| PKG Health (Global Kinetics) | - |
| Q-Sera | - |
| Que Oncology | - |
| Vaxxas | - |
Investors that coverage says has money in a fund Brandon BioCatalyst runs. This is a stake in the fund, not in any company the fund has backed.
| Investor | Fund | Sources |
|---|---|---|
| Australian Government | - | Brandon Capital (Tue 18 Feb 2025), Brandon BioCatalyst (Tue 14 Jan 2025), Brandon Capital (Tue 14 Jan 2025), Brandon BioCatalyst (Sun 26 Nov 2023), Brandon BioCatalyst portfolio (Fri 10 Feb 2023), Brandon BioCatalyst portfolio (Tue 6 Dec 2022), Brandon Capital portfolio |
| CSIRO | CUREator | @AuManufacturing, Brandon Capital portfolio |
| Medical Research Future Fund | CUREator | @AuManufacturing, Brandon Capital portfolio |
| Medical Research Future Fund | Early Stage Translation and Commercialisation Support Grant (ESTAC) | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Companies Brandon BioCatalyst has backed that another company then bought. An exit for the holding, not a deal Brandon BioCatalyst did.
Stories naming Brandon BioCatalyst. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech Kinoxis completed a $6.75 million round with new backer MainSequence and won a $2.5 million government-funded CUREator+ grant for dementia and pain drug development; MainSequence's Elaine Stead joins the board.
Also Startup Daily·Startup Daily·Dealroom·This Week in Australian Startups·Dynamic Business
Melbourne dementia drug developer Kinoxis secured $6.75 million equity led by Main Sequence plus a $2.5 million Medical Research Future Fund grant via CUREator+, funding trials of its agitation and pain drug candidates.
Profile of Denteric, a biotech developing GPV381, an injectable therapy targeting gum bacteria implicated in Alzheimer's disease; the team is seeking backers to fund its first study in patients.
Australian medtech Ceretas hit a milestone in its CUREator+ program, unlocking the final instalment of a government-funded grant; the piece also recaps its A$8 million IPO and ASX listing earlier in 2026.
Six Australian health tech startups received non-dilutive grants totaling $13.5 million from the government-backed CUREator+ program to accelerate commercialisation of medical innovations.
Six Australian biomedical and health ventures receive a combined $13.5 million in non-dilutive grants through round two of the CUREator+ commercialisation program operated by Brandon BioCatalyst and backed by the Medical Research Future Fund.
Also Dealroom
Six Australian health tech startups received a combined $13.5 million in non-dilutive funding from the CUREator+ program, supported by the Australian Government.
Interview with John Shanks, a former hospital pharmacist who founded Kraken Coding to turn clinical guidelines into digital decision-support pathways, now live in Australian health services and Canadian hospitals.
Perth medtech spin-out Cytophenix raised a pre-seed round above its target to advance trials and grow the team behind FloCAST, a rapid test identifying effective antibiotics, after earlier grants and accelerator programs.
Government-backed CUREator+ program awards non-dilutive funding to seven Australian companies developing dementia and cognitive decline therapeutics, devices and digital health tools.
Brandon BioCatalyst has named Peter Beattie its chair as Bill Ferris retires, with Andrew Nash joining the board and Ross King becoming deputy; manager Brandon Capital's newly raised $439 million fund was noted.
Mirugen, a Melbourne biotech spun out of an eye research institute, has closed a A$4.5m seed round with three backers and hired Charlotte Casebourne Stock as chair and acting chief executive.
Also cera.org.au·Brandon BioCatalyst portfolio·insightnews.com.au
Australia's NRFC has injected $150m into Brandon Capital's sixth life-science vehicle, lifting it to a $439m close; past NRFC cheques to local deep-tech firms are also recapped.
Australian biotech PolyActiva has raised A$40 million in Series C funding to advance its PA5108 ocular implant and PREZIA platform, backed by the National Reconstruction Fund Corporation and Brandon Capital.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·SmartCompany·SmartCompany·polyactiva.com·Startup Daily·ophthalmologybreakingnews.com·Forbes Australia
CUREator+, backed by Brandon BioCatalyst, ANDHealth and Dementia Australia, launches second round offering non-dilutive funding to startups targeting dementia and cognitive decline.
Profile of Australian biotech startup Proxima Bio, covering its founding, an early MRFF grant through the CUREator program, Brandon Capital's guidance, and a later larger investment that grew the team.
Vaxxas has finished enrolling 258 volunteers in its Phase I trial of a needle-free HD-MAP avian flu vaccine, funded by a US BARDA contract, with early findings due mid-2025.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·labonline.com.au·SmartCompany·labonline.com.au
Vaxxas has filled its 258-person Phase I trial of a needle-free avian flu vaccine patch, run under a US$28.5 million US government contract; the post also recounts the company's early backing.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·labonline.com.au
Vaxxas has won the concept stage of BARDA's Patch Forward Prize, earning US$2 million (A$3.2 million) to progress its microarray patch vaccine platform alongside the University of Queensland's BASE facility.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·labonline.com.au
Vaxxas wins US$2 million as a concept-stage winner of BARDA's prize to advance its skin-patch vaccine platform with UQ's BASE facility; the article also recalls early backing by OneVentures, Brandon Capital and HealthCare Ventures.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·@AuManufacturing·@AuManufacturing·Business News Australia
Eight Australian health startups received equity-free grants totaling 18.5 million dollars from the CUREator+ program, supported by government funding and delivered with partners Brandon BioCatalyst and ANDHealth.
Brandon BioCatalyst's CUREator incubator has granted an extra $1.865m across four Australian biotechs working on antibiotic prescribing, schizophrenia, muscular dystrophy and autoimmune therapies, on top of their initial awards.
The CUREator+ incubator, backed by government funds and industry partners, launches its initial grant round offering non-dilutive capital to startups developing dementia and cognitive decline solutions.
CUREator, Brandon BioCatalyst's government-backed grant program, has awarded $7.21 million across eight Australian biotech firms in its newest round, split between clinical-stage and preclinical recipients.
Also Brandon BioCatalyst portfolio·Startup Daily·ausceleratesa.org
Brandon BioCatalyst's CUREator biotech incubator has allocated $3 million across five antimicrobial resistance projects, with a UWA-linked nasal spray venture, Spritz-OM, receiving $500,000 toward Phase 1 clinical trials.
Vaxxas reports positive Phase I results for its needle-free skin-patch delivery of a measles-rubella vaccine, with Gates Foundation grant funding and a planned PATH-sponsored Phase I/II trial in The Gambia.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·labonline.com.au
Cicada Innovations is opening a health-tech incubator at Sydney's Westmead precinct with NSW government grant backing, working with Brandon Capital and Brandon BioCatalyst to help researchers commercialise medical discoveries.
Deep tech incubator Cicada Innovations is opening a health-focused facility at Sydney's Westmead precinct with Investment NSW backing, working with Brandon Capital and Brandon BioCatalyst to help early medical startups commercialise.
Biotech incubator CUREator's second round distributes $12 million among 19 health-focused startups, supported by government funding, while a new MedTech program backed by $50 million arrives later in the year.
CUREator, the national biotech incubator operated by Brandon BioCatalyst, selects 19 projects for its second funding round worth $12 million, and a $50 million MRFF award will add a MedTech stream.
Cardiac pacing company EBR Systems says its SOLVE-CRT trial hit its safety and efficacy goals early, keeping a 2024 US approval bid on course; the article also recalls its 2021 ASX listing.
Vaxxas has begun an Australian Phase I trial of its needle-free influenza vaccine patch. The article also recalls the company's founding equity financing led by OneVentures with Brandon Capital Partners and other co-investors.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·labonline.com.au
Vaxxas completed a US$23 million (A$34 million) financing led by OneVentures and UniQuest to advance its needle-free vaccine clinical programs, including a COVID-19 candidate, with board members, management and individual investors also participating.
Also Brandon Capital portfolio·OneVentures portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·SmartCompany·Techboard·labonline.com.au·@AuManufacturing·@AuManufacturing
QUE Oncology reports its non-hormonal drug Q-122 eased hot flushes in breast cancer patients on endocrine therapy, with Phase II results in The Lancet; the Emory–UniQuest venture is backed by Brandon BioCatalyst and Uniseed.
Brandon Capital's blog covers QUE Oncology's Phase II Q-122 results in The Lancet, showing reduced hot flushes and night sweats in breast cancer patients on endocrine therapy.
Vaxxas has begun an Australian Phase I trial of its needle-free COVID-19 vaccine patch; the article also recalls the company's founding financing led by OneVentures with Brandon Capital and other co-investors.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·labonline.com.au
Vaxxas has begun a phase one trial in Australia of its needle-free COVID-19 vaccine patch. The Brisbane company, backed by OneVentures, Brandon Capital and others, has hired Scott Fry from Ellume as COO.
Brisbane biotech Vaxxas has begun human testing of its microneedle patch for COVID-19 vaccination and plans a phase two study; the venture-backed company has raised over $66 million.
Australian biotech OccuRx secured $16 million co-led by Brandon BioCatalyst and Uniseed, including a CUREator grant, to advance its oral anti-fibrosis therapy into kidney disease trials; two executives also joined.
Azura Ophthalmics won a CUREator grant to fund a two-stage study of its AZR-MD-001 candidate for contact lens discomfort, extending pilot research conducted with UNSW; the incubator program is run by Brandon BioCatalyst.